Post-operative Monitoring of Gastric Cancer

Suzhou Huhu Health & Technology Inc.258 enrolled

Overview

This study is to determine the performance of non-invasive new multi-target biomarkers in the post-operative monitoring of gastric cancer.

This study aims to develop and validate a new non-invasive detection method for postoperative monitoring of gastric cancer in the blood. Blood will also be collected at various time points post-operatively. We will determine whether these new biomarkers can be used as prognostic biomarkers to predict tumor recurrence and metastasis. We will also determine whether these new biomarkers detect tumor recurrence and metastasis earlier than methods currently used in the clinic such as imaging and tumor biomarkers CA19-9, CEA, and CA72-4. This study is a prospective and multi-center study.

Study Type

OBSERVATIONAL

Enrollment

258

Conditions

Gastric Cancer

Interventions

DNA testDIAGNOSTIC_TEST

a new non-invasive detection method for postoperative monitoring of gastric cancer in the blood

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subject age over 18. 2. Subject has stomach discomfort, and seek medical attention at the Gastric Surgery Department of our center. 3. Subject has or will have gastroscopy and/or pathological examination results at this center. 4. Subject must be able to fully understand the informed consent form and be able to personally sign it. Exclusion Criteria: 1. Subject has serious heart, liver, kidney dysfunction, or mental illness. 2. Subject diagnosed previously with any kind of malignant tumor. 3. Subject is known to be infected with HIV or other related diseases (considering interference from the use of immune drugs). 4. Subject is receiving targeted drugs, immunosuppressants, immunomodulators, and biological therapies. 5. Researchers believe that subject is not suitable for enrollment. 6. Subject can not supply sufficient sample to complete this experiment.

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

RECRUITING

Outcomes

Primary Outcomes

The performance of the new biomarkers in the post-operative monitoring of gastric cancer

Number of Participants With Tumor Recurrence Detected by the New System vs. Imaging and Serum Markers (CA19-9, CEA, CA72-4).

Time frame: 2 years

Secondary Outcomes

Metastasis Detection Time: New vs. Conventional Methods

Time to Detection of Metastasis (Days) by the New System Compared to Conventional Methods.

Time frame: 2 years

Central Contacts

Dazhi Xu, MD., PhD,

CONTACT

+86 13862036541 jiangnan@sz-hoho.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.